Dr Consuelo Bertossi speaks to ecancer at EHA 2024.

In her study of 10,051 CLL patients, TP53 mutations were linked to significantly poorer progression-free survival (PFS) and overall survival (OS), regardless of the mutation type.

Patients with multiple TP53 mutations or concurrent del(17p) fared the worst.

The negative impact of TP53 mutations was more pronounced in those receiving chemoimmunotherapy compared to targeted therapies, with ibrutinib-based regimens showing less impact.

TP53 predicts shorter PFS and OS, irrespective of the IGHV mutation status.